ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2621

Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution

TC Salman-Monte1, Eva Rodriguez2, José Luis Arevalos3, María José Soler3, Clara Barrios3, Jordi Carbonell4 and Julio Pascual3, 1Rheumatology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, 2Nephrology, Hospital del Mar/ Parc de Salut Mar, Barcelona, Spain, 3Nephrology, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain, 4Rheumatology Unit, Hospital del Mar/Parc de Salut Mar, Barcelona, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Nephritis, proteinuria, renal disease and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment Poster III: Therapeutics and Clinical Trial Design

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:

Lupus nephritis (LN) is the most common organ involvement in Systemic Lupus Erythematosus (SLE). Indications of renal biopsy (RB) are deterioration of renal function and / or activity in sediment and / or proteinuria> 0.5g / 24h or urine protein: creatinine ratio (P:C ratio) > 0.5 (SEN consensus 2012). There are patients who show data of “minimal renal involvement” (MRI) without indication of RB. Our objective is to determine if these patients present clinical and analytical characteristics that allow them to differentiate from patients with LN.

Methods:

We reviewed 171 patients with SLE diagnosis, classifying them as MRI if they showed> 3 occasions at least 1 year, proteinuria determinations = 0.3 g / 24h or P:C ratio= 0.3, ruling out urologic pathology. We have compared clinical and analytical variables of MRI vs LN at the time of SLE diagnosis, at renal involvement diagnosis and last visit.

Results:

We identified 38 (18.7%) patients with MRI and 41 (24%) patients with LN. At the time of SLE diagnosis, the MRI group had a lower titer of anti-DNAds (14.8% vs 42.1%, p = 0.01), anti-Sm (12% vs 32.2%, p = 0.04), presence of lupus anticoagulant (38%, p = 0.01) and anticardiolipin IgG (11% vs 38%, p = 0.01), less severe C3 hypocomplementemia (70 ± 34 vs 86.9 ± 32.7 mg / dl, p = 0.04), C4 (14 ± 10 vs 17 (p = 0.04) and CH50 (33.3 ± 15 vs 49.6 ± 17.4 mg / dl, p = 0.04); and lower inflammatory parameters: ESR (23.1 ± 20 vs 58.9 ± 42 mg / dl, p = 0.01), CRP (12.7±11.8 vs 27.3±17 mg/dl, p=0.02). At the diagnosis of the renal involvement, these results were confirmed (Table) and we observed that, in MRI patients, proteinuria appeared at an older age, with a higher evolution of SLE (12.7 ± 11.8 vs 27.3 ± 17 mg / dl, p = 0.02) and with absence of previous immunosuppressant therapy. After a mean follow-up of 10 ± 6.6 years, no MRI patient presented a renal flare, maintaining stable the renal function.

LUPUS NEPHRITIS

(n=41)

MINIMAL RENAL INVOLVEMENT (MRI) n=38

p

Sex (Female/Male)

30/11

29/3

0.05

Age (years)

38 ± 16

45 ± 17

0.07

Follow up time (years)

3.4 ± 5.5

5.8 ± 4

0.01

Creat (mg/dl)

1.3 ± 1.3

0.7 ± 0.2

0.02

URINE SEDIMENT

  • Negative

  • Hematuria

  • Leukocyturia

  • Changes in sediment

14 (35%)

3 (7,5%)

9 (22.5%)

14 (35%)

32 (100%)

NA

Proteinuria (mg/24h)

2044 ± 2700

266 ± 71.6

NA

(P:C ratio) (mg/gr)

1761,7 ±1446

232 ± 172

NA

HT (n, %)

3 (13%)

2 (6%)

0.6

DM2 (n, %)

2 (8%)

2 (6%)

0.7

DNA-crithiida

26 (74.3)

9 (37.5)

0.005

Anti-SSARO (IA)

13 (38.2%)

12 (38.7%)

0.5

Anti-La (IA)

8 (23.5%)

5 (16.1%)

0.3

Anti-RNP (IA)

13 (39.4%)

7 (24.1%)

0.1

Anti-Sm (IA)

13 (39.4%)

4 (14.3%)

0.002

C3 (mg/dl)

70±21.9

130±10

0.001

C4 (mg/dl)

16.1±3.9

26±10.8

0.001

C1q (mg/dl)

16.5±11

26±12.3

0.001

CH50 (U/mL)

34±5.3

71.0±15

0.001

Immunosuppressants

  • Micophenolic acid

  • Azathioprine

  • Hydroxyclorochine

15 (38.5%)

20%

13%

20%

25 (78,1%)

4%

88%

32%

0.001

0.1

0.001

0.003

Corticosteroids

19 (50%)

15 (46.9%)

0.4

Conclusion:

Our results showed that patients with MRI had a lower clinical and biological SLE activity, both at SLE diagnosis and at the diagnosis of renal involvement. No MRI patients presented a LN flare during the follow-up although it is difficult to know the role played by the immunosuppressant treatment.



Disclosure: T. Salman-Monte, None; E. Rodriguez, None; J. L. Arevalos, None; M. J. Soler, None; C. Barrios, None; J. Carbonell, None; J. Pascual, None.

To cite this abstract in AMA style:

Salman-Monte T, Rodriguez E, Arevalos JL, Soler MJ, Barrios C, Carbonell J, Pascual J. Minimal Renal Affection in Patients with Systemic LUPUS Erythematosus: Characteristics and Evolution [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/minimal-renal-affection-in-patients-with-systemic-lupus-erythematosus-characteristics-and-evolution/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/minimal-renal-affection-in-patients-with-systemic-lupus-erythematosus-characteristics-and-evolution/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology